DIGIPREDICT: physiological, behavioural and environmental predictors of asthma attacks-a prospective observational study using digital markers and artificial intelligence-study protocol.

Autor:	Chan AHY; School of Pharmacy, The University of Auckland Faculty of Medical and Health Sciences, Auckland, Region, New Zealand a.chan@auckland.ac.nz., Te Ao B; School of Population Health, University of Auckland, Auckland, New Zealand., Baggott C; Department of Respiratory Medicine and Respiratory research unit, Waikato Hospital, Hamilton, New Zealand., Cavadino A; School of Population Health, University of Auckland, Auckland, New Zealand., Eikholt AA; University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD, Groningen, Netherlands.; Medication Adherence Expertise Center of the northern Netherlands (MAECON), Groningen, Netherlands., Harwood M; School of Population Health, University of Auckland, Auckland, New Zealand., Hikaka J; Te Kupenga Hauora Māori, University of Auckland, Auckland, New Zealand., Gibbs D; Pinnacle Midlands Health Network, Hamilton, New Zealand., Hudson M; School of Pharmacy, The University of Auckland Faculty of Medical and Health Sciences, Auckland, Region, New Zealand., Mirza F; Department of IT and Software Engineering, Auckland University of Technology, Auckland, New Zealand., Naeem MA; Department of IT and Software Engineering, Auckland University of Technology, Auckland, New Zealand.; National University of Computer and Emerging Sciences, Islamabad, Pakistan., Semprini R; Medical Research Institute of New Zealand, Wellington, New Zealand., Chang CL; Department of Respiratory Medicine and Respiratory research unit, Waikato Hospital, Hamilton, New Zealand., Tsang KCH; University College London, London, UK.; The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, Edinburgh, UK., Shah SA; The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, Edinburgh, UK., Jeremiah A; Department of Electrical, Computer and Software Engineering, University of Auckland, Auckland, New Zealand., Abeysinghe BN; Department of Electrical, Computer and Software Engineering, University of Auckland, Auckland, New Zealand., Roy R; Department of Nutrition and Dietetics, University of Auckland, Auckland, New Zealand., Wall C; Department of Nutrition and Dietetics, University of Auckland, Auckland, New Zealand., Wood L; Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia., Dalziel S; Children's Emergency Department, Starship Children's Hospital, Auckland, New Zealand., Pinnock H; The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, Edinburgh, UK., van Boven JFM; University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD, Groningen, Netherlands.; Medication Adherence Expertise Center of the northern Netherlands (MAECON), Groningen, Netherlands., Roop P; Department of Electrical, Computer and Software Engineering, University of Auckland, Auckland, New Zealand., Harrison J; School of Pharmacy, The University of Auckland Faculty of Medical and Health Sciences, Auckland, Region, New Zealand.
Jazyk:	angličtina
Zdroj:	BMJ open respiratory research [BMJ Open Respir Res] 2024 May 22; Vol. 11 (1). Date of Electronic Publication: 2024 May 22.
DOI:	10.1136/bmjresp-2023-002275
Abstrakt:	Introduction: Asthma attacks are a leading cause of morbidity and mortality but are preventable in most if detected and treated promptly. However, the changes that occur physiologically and behaviourally in the days and weeks preceding an attack are not always recognised, highlighting a potential role for technology. The aim of this study 'DIGIPREDICT' is to identify early digital markers of asthma attacks using sensors embedded in smart devices including watches and inhalers, and leverage health and environmental datasets and artificial intelligence, to develop a risk prediction model to provide an early, personalised warning of asthma attacks. Methods and Analysis: A prospective sample of 300 people, 12 years or older, with a history of a moderate or severe asthma attack in the last 12 months will be recruited in New Zealand. Each participant will be given a smart watch (to assess physiological measures such as heart and respiratory rate), peak flow meter, smart inhaler (to assess adherence and inhalation) and a cough monitoring application to use regularly over 6 months with fortnightly questionnaires on asthma control and well-being. Data on sociodemographics, asthma control, lung function, dietary intake, medical history and technology acceptance will be collected at baseline and at 6 months. Asthma attacks will be measured by self-report and confirmed with clinical records. The collected data, along with environmental data on weather and air quality, will be analysed using machine learning to develop a risk prediction model for asthma attacks. Ethics and Dissemination: Ethical approval has been obtained from the New Zealand Health and Disability Ethics Committee (2023 FULL 13541). Enrolment began in August 2023. Results will be presented at local, national and international meetings, including dissemination via community groups, and submission for publication to peer-reviewed journals. Trial Registration Number: Australian New Zealand Clinical Trials Registry ACTRN12623000764639; Australian New Zealand Clinical Trials Registry. Competing Interests: Competing interests: AHYC reports research grants from Health Research Council of New Zealand, Auckland Medical Research Foundation, Asthma UK, University of Auckland, Oakley Mental Health Foundation, Chorus Ltd, World Health Organisation, and Hong Kong University, outside the submitted work and all paid to her institution (the University of Auckland). She is the previous holder of a Robert Irwin Postdoctoral Fellowship. AHYC also reports consultancy fees from AcademyeX and Spoonful of Sugar Ltd, and is also a Board member of Asthma NZ., member of Respiratory Effectiveness Group (REG) and working group lead for the European Respiratory Society Clinical Research Collaboration 'CONNECT'. JFMvB reports grants from Aardex, grants and personal fees from AstraZeneca, grants and personal fees from Chiesi, grants from European Commission COST Action 'ENABLE' (CA19132), grants from European Respiratory Society for the Clinical Research Collaboration 'CONNECT', personal fees from GSK, grants and personal fees from Novartis, personal fees from Teva, grants and personal fees from Trudell Medical and personal fees from Vertex, outside the submitted work and all paid to his institution (UMCG).JH reports research grants from Health Research Council of New Zealand, Auckland Medical Research Foundation, University of Auckland, outside the submitted work and all paid to her institution (the University of Auckland). HP reports research grants from National Institute for Health and Care Research, European Respiratory Society and UK Medical Research Council paid to her University for applied and implementation research on models of care for non-communicable respiratory disease. Within the last 3 years, she has contributed to sponsored symposia (Teva Pharmaceuticals and Sandoz UK) on topics related to delivery of care and digital health. CB reports personal fees and honorarium from AstraZeneca and GSK outside of the submitted work.LW reports research grants from National Health and Medical Research Council of Australia, Medical Research Futures Fund, National Institutes of Health USA, John Hunter Hospital Charitable Trust, Hunter Medical Research Institute, Noumi Foods Pty Ltd, Lifecykel Labs Pty Ltd, Department of Industry, Innovation and Science, outside of the submitted work and all paid to her institution (University of Newcastle, Australia). Within the last 3 years, she has contributed to sponsored symposia (Sanofi, Boehringer-Ingelheim) on topics related to nutrition and respiratory disease. SD reports research grants from Health Research Council of New Zealand, Auckland Medical Research Foundation, Starship Foundation, Lottery Grants Board, Cure Kids New Zealand, National Health and Medical Research Council of Australia, Medical Research Futures Fund outside the submitted work and all paid to his institutions (the University of Auckland/Starship Children’s Hospital). All other authors have no interests to disclose. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu